NO20052363D0 - Interferon-alfa polypeptider og konjugater - Google Patents
Interferon-alfa polypeptider og konjugaterInfo
- Publication number
- NO20052363D0 NO20052363D0 NO20052363A NO20052363A NO20052363D0 NO 20052363 D0 NO20052363 D0 NO 20052363D0 NO 20052363 A NO20052363 A NO 20052363A NO 20052363 A NO20052363 A NO 20052363A NO 20052363 D0 NO20052363 D0 NO 20052363D0
- Authority
- NO
- Norway
- Prior art keywords
- conjugates
- interferon
- alpha polypeptides
- polypeptides
- alpha
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title 1
- 108010047761 Interferon-alpha Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42761202P | 2002-11-18 | 2002-11-18 | |
| US50256003P | 2003-09-12 | 2003-09-12 | |
| PCT/US2003/036682 WO2004046365A2 (en) | 2002-11-18 | 2003-11-17 | Interferon-alpha polypeptides and conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052363D0 true NO20052363D0 (no) | 2005-05-12 |
| NO20052363L NO20052363L (no) | 2005-08-08 |
Family
ID=32329174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052363A NO20052363L (no) | 2002-11-18 | 2005-05-12 | Interferon-alfa polypeptider og konjugater |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040219131A1 (no) |
| EP (1) | EP1565205A4 (no) |
| JP (1) | JP2006506097A (no) |
| KR (1) | KR20050086498A (no) |
| AU (1) | AU2003297285A1 (no) |
| BR (1) | BR0316324A (no) |
| CA (1) | CA2504267A1 (no) |
| IL (1) | IL168049A0 (no) |
| MX (1) | MXPA05005263A (no) |
| NO (1) | NO20052363L (no) |
| NZ (1) | NZ540043A (no) |
| RU (1) | RU2005118998A (no) |
| WO (1) | WO2004046365A2 (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| US7959910B2 (en) * | 2000-07-31 | 2011-06-14 | Biolex Therapeutics, Inc. | C-terminally truncated interferon alpha variants |
| EP1539960B1 (en) * | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Protease-resistant modified interferon alpha polypeptides |
| TWI364295B (en) | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| AU2003303635B2 (en) | 2002-12-26 | 2009-07-23 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| CA2516552A1 (en) * | 2003-02-26 | 2004-09-10 | Intermune, Inc. | Polyethylene glycol modified interferon compositions and methods of use thereof |
| CA2553528C (en) * | 2004-01-21 | 2012-12-04 | Nektar Therapeutics Al, Corporation | Method of preparing propionic acid-terminated polymers |
| MXPA06013412A (es) * | 2004-05-19 | 2007-01-23 | Maxygen Inc | Polipeptidos de interferon-alfa y conjugados. |
| US20060029573A1 (en) * | 2004-06-30 | 2006-02-09 | Chun Shen | Pegylated interferon alpha-1b |
| US20060024272A1 (en) * | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| WO2006053131A1 (en) | 2004-11-11 | 2006-05-18 | Modular Genetics, Inc. | Ladder assembly and system for generating diversity |
| US9931413B2 (en) * | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US20070054360A1 (en) * | 2005-05-12 | 2007-03-08 | Zeren Gao | Compositions and methods for modulating immune responses |
| AU2006299901A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| KR101470472B1 (ko) | 2006-09-14 | 2014-12-09 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
| CN1970572A (zh) * | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| WO2008124086A2 (en) * | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| KR101591887B1 (ko) | 2010-06-15 | 2016-02-04 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
| US20130225789A1 (en) * | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
| WO2023023283A2 (en) * | 2021-08-18 | 2023-02-23 | Remd Biotherapeutics, Inc. | Novel interferon variants and bifunctional fusion molecules thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| IE54592B1 (en) * | 1982-03-08 | 1989-12-06 | Genentech Inc | Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| ATE78262T1 (de) * | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| DE60035871T2 (de) * | 1999-05-19 | 2008-06-05 | Merck Patent Gmbh | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
| AU8001300A (en) * | 1999-10-07 | 2001-05-10 | Maxygen, Inc. | Ifn-alpha homologues |
| US20020025304A1 (en) * | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| WO2002044197A2 (en) * | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| EP1562634B1 (en) * | 2002-11-15 | 2006-08-23 | F. Hoffmann-La Roche Ag | Positional isomers of pegylated interferon alpha 2a |
-
2003
- 2003-11-17 BR BR0316324-5A patent/BR0316324A/pt not_active Application Discontinuation
- 2003-11-17 EP EP03811632A patent/EP1565205A4/en not_active Withdrawn
- 2003-11-17 WO PCT/US2003/036682 patent/WO2004046365A2/en active Application Filing
- 2003-11-17 KR KR1020057008337A patent/KR20050086498A/ko not_active Application Discontinuation
- 2003-11-17 NZ NZ540043A patent/NZ540043A/en unknown
- 2003-11-17 US US10/714,817 patent/US20040219131A1/en not_active Abandoned
- 2003-11-17 MX MXPA05005263A patent/MXPA05005263A/es not_active Application Discontinuation
- 2003-11-17 RU RU2005118998/15A patent/RU2005118998A/ru not_active Application Discontinuation
- 2003-11-17 JP JP2004570419A patent/JP2006506097A/ja active Pending
- 2003-11-17 CA CA002504267A patent/CA2504267A1/en not_active Abandoned
- 2003-11-17 AU AU2003297285A patent/AU2003297285A1/en not_active Abandoned
-
2005
- 2005-04-14 IL IL168049A patent/IL168049A0/en unknown
- 2005-05-12 NO NO20052363A patent/NO20052363L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05005263A (es) | 2005-07-25 |
| WO2004046365A2 (en) | 2004-06-03 |
| IL168049A0 (en) | 2009-02-11 |
| JP2006506097A (ja) | 2006-02-23 |
| NZ540043A (en) | 2007-11-30 |
| KR20050086498A (ko) | 2005-08-30 |
| NO20052363L (no) | 2005-08-08 |
| BR0316324A (pt) | 2005-09-27 |
| US20040219131A1 (en) | 2004-11-04 |
| CA2504267A1 (en) | 2004-06-03 |
| EP1565205A4 (en) | 2006-07-05 |
| EP1565205A2 (en) | 2005-08-24 |
| RU2005118998A (ru) | 2006-01-27 |
| WO2004046365A3 (en) | 2004-09-02 |
| AU2003297285A1 (en) | 2004-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052363D0 (no) | Interferon-alfa polypeptider og konjugater | |
| DK1519770T3 (da) | Elektroporesisk indretning og indsprøjtningsapparat | |
| DK2418220T3 (da) | Interferon-alpha-antistoffer og anvendelser deraf | |
| IL178470A0 (en) | Interferon-alpha polypeptides and conjugates | |
| IS2504B (is) | Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra | |
| NO20040246L (no) | TACI'er- og BR3-polypeptider og anvendelser derav | |
| DK1370128T3 (da) | Kombineret ballepresse og ballevikler | |
| NO20052524D0 (no) | Aminerte isofiavonoidderivater og anvendelse derav | |
| IS8458A (is) | Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit | |
| DK1641822T3 (da) | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. | |
| NO20044192L (no) | 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater | |
| DK1404809T3 (da) | Forbedrede hudsubstitutter og anvendelser deraf | |
| IL165249A0 (en) | Hapten-carrier conjugates and uses thereof | |
| DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
| IS8453A (is) | Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit | |
| DK1554250T3 (da) | Hidtil ukendt lactamer og anvendelser deraf | |
| DK1484347T3 (da) | Harpikssammensætning og optiske elementer | |
| DK1663291T3 (da) | Rekombinante lubricinmolekyler og anvendelser deraf | |
| IS8455A (is) | Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit | |
| IS7783A (is) | Flóð og fjöru-ker | |
| IS2841B (is) | Samstæða hluta og lyfjasamsetningar | |
| DK1068238T3 (da) | Integrinheterodimer og subunit deraf | |
| NO20034820L (no) | Fastspenningsenhet og snoscooter omfattende en fastspenningsenhet | |
| AU2003214625A8 (en) | Histone conjugates and uses thereof | |
| NO20023144D0 (no) | Kompleks omfattende OCIF og polysakkarid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |